研究单位：[1]Study Principal Investigator[2]Sun Yat-sen University[3]Tongji Hospital[4]Sichuan Cancer Hospital and Research Institute[5]The First Affiliated Hospital of Zhengzhou University[6]West China Hospital[7]Zhejiang University[8]Jilin Provincial Tumor Hospital[9]Hunan Cancer Hospital[10]Shandong Cancer Hospital and Institute[11]Jiangxi Provincial Cancer Hospital[12]First Hospital of China Medical University[13]The Affiliated Hospital of Qingdao University[14]Liaoning Tumor Hospital & Institute[15]Haerbin Medical University Cancer Hospital[16]Xinxiang Central Hospital[17]Xiangyang Central Hospital[18]Mianyang Central Hospital[19]Zhejiang Cancer Hospital[20]Henan Cancer Hospital[21]First Affiliated Hospital, Sun Yat-Sen University[22]First Affiliated Hospital of Bengbu Medical College[23]Chinese Academy of Medical Science Cancer Hospital, Shenzhen Center[24]Bingzhou Medical University Affiliated Hospital[25]Fujian Cancer Hospital[26]Ningbo No. 1 Hospital[27]First Affiliated Hospital Xi'an Jiaotong University[28]The Second Affiliated Hospital of AFMU[29]Yunnan Cancer Hospital[30]Capital Medical School Beijing Chest Hospital[31]Shijiazhuang People's Hospital[32]Tianjin Cancer Hospital[33]Affiliated Cancer Hospital of Guizhou Medical University[34]Nanchang University First Affiliated Hospital[35]Jingzhou First People's Hospital[36]Shanghai Chest Hospital
研究目的：
This is a multi-center, single-arm, open-label, Phase II clinical trial which explores the safety and efficacy of TGRX-326 in patients with ALK-positive advanced NSCLC who have failed prior 2nd-generation ALK treatments due to progressive disease or intolerance.
